- October 01, 2020Source: OncLive
Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research
- September 24, 2020
Yale Cancer Center Awarded NIH SPORE for Head and Neck Cancer Research
- October 01, 2019
Transformative Treatments for Head and Neck Cancers
- May 01, 2019Source: Fox Chase Cancer Center
Fox Chase Cancer Center Appoints Five New Endowed Chairs
Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE)
Overcoming treatment resistance in Head and Neck Cancer
Yale Cancer Center was awarded a five-year, $11.7 million grant from the National Institutes of Health (NIH) to fund the Yale Head and Neck Cancer Specialized Program of Research Excellence (SPORE). The SPORE program harnesses the strengths of academic cancer centers by bringing together experts in oncology, immunobiology, pharmacology, molecular biology, pathology, epidemiology, and addiction science to collaborate on projects. The goal of the Yale Head and Neck Cancer SPORE (YHN-SPORE) is to address critical barriers to treatment of head and neck squamous cell carcinoma (HNSCC) due to resistance to immune, DNA damaging, and targeted therapy.
Projects
- The epidermal growth factor receptor (EGFR) remains the only validated molecular target in head and neck squamous cell carcinoma (HNSCC), mediating cell survival signaling and resistance to radiation therapy.
- HPV-negative head and neck squamous cell carcinomas (HNSCC) typically lose G1/S cell cycle checkpoints, with most tumors having mutations in TP53, and many also mutating other tumor suppressors such as CDKN2A.
- Human papillomavirus (HPV)-associated neck squamous cell carcinoma (HNSCC) represents an increasing proportion of HNSCC.